Guggenheim analyst Eddie Hickman raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $84 from $78 and keeps a Buy rating on the shares. The firm has updated its model to reflect the updated spend, script volume, and GTN guidance following the company’s Q1 report.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth
- Tarsus Pharmaceuticals reports Q1 EPS (64c), consensus (63c)
- Tarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meeting
- Tarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50
- Tarsus Pharmaceuticals announces $100M common stock offering